Compare WBI & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WBI | TBPH |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 940.1M | 1.0B |
| IPO Year | 2025 | N/A |
| Metric | WBI | TBPH |
|---|---|---|
| Price | $23.01 | $20.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $27.25 | ★ $27.80 |
| AVG Volume (30 Days) | ★ 519.3K | 358.2K |
| Earning Date | 03-16-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.58 |
| Revenue | ★ $733,296,000.00 | $80,327,000.00 |
| Revenue This Year | $21.70 | $70.78 |
| Revenue Next Year | $12.32 | N/A |
| P/E Ratio | ★ N/A | $35.29 |
| Revenue Growth | N/A | ★ 27.12 |
| 52 Week Low | $18.64 | $7.90 |
| 52 Week High | $27.12 | $21.03 |
| Indicator | WBI | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 56.10 | 53.35 |
| Support Level | $21.46 | $18.78 |
| Resistance Level | $22.52 | $20.50 |
| Average True Range (ATR) | 0.87 | 0.78 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 38.46 | 44.00 |
WaterBridge Infrastructure LLC is integrated, pure-play water infrastructure company with operations predominantly in the Delaware Basin, the prolific oil and natural gas basin in North America. It operates the largest produced water infrastructure network in the United States through which it provides water management solutions to oil and natural gas E&P companies under long-term contracts, which include gathering, transporting, recycling and handling produced water. It also operate two energy waste management facilities for the disposal of non-hazardous waste resulting from oil and gas E&P activities, branded under Desert Environmental. The transportation, treatment and handling of produced water is crucial to oil and natural gas production.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).